Trial Profile
A Multi-center, Randomized, Double-blind, Controlled, and Parallel Phase III Study to Compare the Efficacy and Safety of GB241 (Recombinant Anti-CD20 Human-Mouse Chimeric Monoclonal Antibody Injection, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated Diffuse Large B-cell Lymphoma (DLBCL) Patients
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Vincristine (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Nanjing Yoko Biomedical
- 18 Feb 2024 Planned End Date changed from 1 Oct 2021 to 31 Dec 2025.
- 18 Feb 2024 Status changed from not yet recruiting to recruiting.
- 06 Sep 2018 New trial record